Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

Moderna earned $5.4 billion in U.S. revenues in 2021 and $4.4 billion in 2022 from COVID-19 vaccine sales. Northwestern University’s nanotechnology research institute, IIN, has supported over $2 ...

Oct 16 (Reuters) - Moderna (MRNA.O), opens new tab was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the ...

The Cambridge, Massachusetts-based company said it had profit of 3 cents per share. The results surpassed Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment ...

Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have lost significantly in the past couple of years due to declining sales amid low demand ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker ...

This time, we have GSK (GSK) "GSK" filing a lawsuit against Moderna (NASDAQ:MRNA) accusing them of patent infringement on their lipid nanoparticle (LNP) technology, which is used in mRNA therapeutics.

Cost of sales dropped 77% thanks to well-managed costs and strategic pivots. Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related ...

Tyler Van Buren’s rating is based on several factors influencing Moderna’s financial outlook. The analyst has adjusted the company’s expense projections downward, reflecting a more ...